Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (881-890 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|February 14, 2012
Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometryCatalin E Doneanu, Alex Xenopoulos, Keith Fadgen, et al.
Mabs|March 29, 2012
IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CAJohan Nilvebrant, D Cameron Dunlop, Aroop Sircar, et al.
Mabs|March 29, 2012
Mabs's communication networksJanice M Reichert
Mabs|March 29, 2012
Monoclonal antibodies directed against human FcRn and their applicationsGregory J Christianson, Victor Z Sun, Shreeram Akilesh, et al.
Mabs|March 29, 2012
Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphomaSu Li, Dongsheng Zhang, Jian Sun, et al.
Mabs|April 16, 2011
Intellectual property protection: strategies for antibody inventionsUlrich Storz
Mabs|June 24, 2011
Development of an Fn14 agonistic antibody as an anti-tumor agentJennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, et al.
Mabs|August 5, 2011
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker designEnrico L Digiammarino, John E Harlan, Karl A Walter, et al.
Mabs|June 10, 2011
Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxisDelphine Mariotte, Benoît Dupont, Radj Gervais, et al.
Mabs|July 26, 2011
Bacterial expression and characterization of a novel human anti-IgE scFv fragmentMingRong Wang, YongXia Zhang, TianFei Du, et al.
Pageof 184

Showing results (881-890 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|February 14, 2012
Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometryCatalin E Doneanu, Alex Xenopoulos, Keith Fadgen, et al.
Mabs|March 29, 2012
IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CAJohan Nilvebrant, D Cameron Dunlop, Aroop Sircar, et al.
Mabs|March 29, 2012
Mabs's communication networksJanice M Reichert
Mabs|March 29, 2012
Monoclonal antibodies directed against human FcRn and their applicationsGregory J Christianson, Victor Z Sun, Shreeram Akilesh, et al.
Mabs|March 29, 2012
Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphomaSu Li, Dongsheng Zhang, Jian Sun, et al.
Mabs|April 16, 2011
Intellectual property protection: strategies for antibody inventionsUlrich Storz
Mabs|June 24, 2011
Development of an Fn14 agonistic antibody as an anti-tumor agentJennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, et al.
Mabs|August 5, 2011
Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker designEnrico L Digiammarino, John E Harlan, Karl A Walter, et al.
Mabs|June 10, 2011
Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxisDelphine Mariotte, Benoît Dupont, Radj Gervais, et al.
Mabs|July 26, 2011
Bacterial expression and characterization of a novel human anti-IgE scFv fragmentMingRong Wang, YongXia Zhang, TianFei Du, et al.
Pageof 184